Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 15/20 | 0.54 |
| ▸ | CA9 | Q16790 | 13/20 | 0.54 |
| ▸ | CA12 | O43570 | 9/20 | 0.54 |
| ▸ | CA7 | P43166 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770531 | 0.85 | PTGS2 (0.43) | CA2SMN1; SMN2 | |
| SCHEMBL4765265 | 0.85 | ATM (0.41) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL4763911 | 0.81 | ALDH1A1 (0.43) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL1983658 | 0.80 | TSHR (0.32) | TSHR | |
| SCHEMBL3846515 | 0.79 | LMNA (0.44) | SMN1; SMN2 | |
| SCHEMBL4774829 | 0.79 | SMN1; SMN2 (0.47) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL28083647 | 0.79 | CA2 (0.43) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL4769186 | 0.78 | LMNA (0.56) | SMN1; SMN2TSHR | |
| SCHEMBL4768844 | 0.78 | ALDH1A1 (0.54) | CA2SMN1; SMN2CA1CA9CA12 | |
| SCHEMBL4763544 | 0.77 | CA12 (0.57) | CA2SMN1; SMN2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| WO-2004039762-A1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| EP-1157025-B1 | PYRAZOLOPYRIDINES | GLAXO GROUP LTD (GB) | 2004-03-10 | — | — | EP | disclosed |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2003-03-06 | — | — | US | disclosed |
| EP-0875506-B1 | Quinoline and quinazoline compounds useful in therapy | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6498166-B1 | POTENT AND SELECTIVE INHIBITORS OF CYCLOOXYGENASE-2; TREATING PAIN, FEVER AND INFLAMMATION | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1157025-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000052008-A1 | PYRAZOLOPYRIDINES | GLAXO GROUP LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999021859-A1 | AZAOXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | WO | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045525-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, BPHL | CA2 1349/4885SMN1; SMN2 3252/4885CA1 3294/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CA2 120/4885SMN1; SMN2 27/4885CA1 517/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | CA2 1298/4885SMN1; SMN2 4615/4885CA1 2848/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | CA2 1387/4885SMN1; SMN2 3191/4885CA1 3243/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | CA2 117/4885SMN1; SMN2 37/4885CA1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.